Preclinical Work May Lay Groundwork for Future Targeted Acne Therapies
April 26, 2024
-
2 min
8 Key Takeaways
-
1
Factors contributing to functional divergence of Cutibacterium acnes bacteria
-
2
Different phylotypes of C acnes bacteria may be associated with acne or healthy skin
-
3
Evolution of two strains of the enzyme hyaluronidase A and B
-
4
Potential of targeting hyaluronidase A in acne treatment
-
5
Conclusion of the study authors from the University of California, San Diego
-
6
Implications of peptide vaccine or inhibitor in anti-acne therapies
-
7
Revolutionary approach in acne treatments
-
8
Preservation of the healthy skin microbiome
The recent study published in Nature Communications by Hajam et al delves into the factors contributing to the functional divergence of human commensal Cutibacterium acnes bacteria. Researchers have identified different phylotypes of C acnes bacteria that may be associated with acne or healthy skin, implicating the evolutionary divergence of enzyme hyaluronidase A and B. The study suggests that targeting hyaluronidase A with a peptide vaccine or inhibitor may offer more directed and effective anti-acne therapies while preserving the healthy skin microbiome, revolutionizing acne therapies.
Listen Tab content
